Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Glimipack MV 1/0.3 Tablet SR is used in the treatment of type 2 diabetes.
30 tablet sr in 1 strip
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Glimipack MV 1/0.3 Tablet SR is to be taken with food.
Glimipack MV 1/0.3 Tablet SR may cause stomach upset if taken on empty stomach.
Glimipack MV 1/0.3 Tablet SR is a combination of three antidiabetic medicines: Glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body"s sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents the blood glucose levels from rising to very high levels after meals.
Related Warnings
Taking Voglibose with alcohol reduce the blood sugar levels in diabetic patients.
Glimipack MV 1/0.3 Tablet SR may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Glimipack MV 1/0.3 Tablet SR is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Your ability to drive may be affected if your blood sugar is low or high. If this happens, do not drive.
Glimipack MV 1/0.3 Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Glimipack MV 1/0.3 Tablet SR may be needed. Please consult your doctor.
Use of Glimipack MV 1/0.3 Tablet SR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Glimipack MV 1/0.3 Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Glimipack MV 1/0.3 Tablet SR may be needed. Please consult your doctor.
Glimipack MV 1/0.3 Tablet SR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
